Last reviewed · How we verify
MEGLUMINE
Meglumine is a compound that works by
Meglumine is a small molecule compound originally developed by an unknown entity. Its current owner is also unknown. The target and drug class of Meglumine are not specified. It is not known whether Meglumine is FDA approved or has any approved indications. The commercial status of Meglumine, including whether it is patented or generic, is also unknown.
At a glance
| Generic name | MEGLUMINE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Mechanism of action
Meglumine is a compound that works by acting as a stabilizer or carrier for other medications, helping them to be more effective and stable in the body. It does not have a direct therapeutic effect on its own, but rather supports the action of other drugs. This can make it easier for patients to take their medications and for healthcare providers to administer them.
Approved indications
Boxed warnings
- NOT FOR INTRATHECAL USE
Common side effects
- Inappetence
- Diarrhea
- Decreased water consumption
- Injection site swelling
Serious adverse events
- Anaphylaxis
- Collapse
- Anaphylactic-like reactions
- Fatal anaphylactic-like reactions
Key clinical trials
- Dotarem vs Gadobutrol Contrast for Breast MRI (PHASE4)
- Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet (PHASE1)
- Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas (PHASE3)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease (PHASE3)
- Diffusion MRI in Heart Failure (EARLY_PHASE1)
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) (PHASE3)
- Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEGLUMINE CI brief — competitive landscape report
- MEGLUMINE updates RSS · CI watch RSS